Glenmark Pharmaceuticals Ltd (GPL) has agreed to divest 75 per cent stake in its subsidiary Glenmark Life Sciences to Nirma Limited at a price of Rs 615 per share, implying an equity valuation of Rs 7,535.4 crore.
The research-led, integrated, global pharmaceutical company has entered into a definitive agreement with Nirma Limited to divest 75 per cent stake in its subsidiary, Glenmark Life Sciences (GLS), at a price of Rs 615 per share for an aggregate consideration of Rs 5,651.5 crore, subject to closing adjustments.
Glenmark Pharma will own 7.84 per cent in GLS after the divestment. The transaction is subject to customary closing conditions precedent, including receipt of regulatory and shareholder approvals.
Pursuant to the transaction, Nirma Limited will make a mandatory open offer to all the public shareholders of GLS.
GPL expects to utilise the proceeds of the sale to repay debt and become net cash positive.
Upon the completion of the transaction and the open offer, the buyer will become the new promoter of the company. GPL will retain 9,609,571 equity shares representing 7.84 per cent of the current issued and paid-up equity share capital of the company.
Pursuant to the transaction, GPL and the other member of the promoter group are proposed to be reclassified as public shareholders.
GPL has agreed that it shall not sell the equity shares retained by it upon the completion of the transaction until the earlier of one year from the closing under the share purchase agreement and one month from the date of compliance with minimum public shareholding requirements by the company and the buyer.
India steps up vigil against cheap Chinese imports amid US tariff hike
India has stepped up vigil to prevent the dumping of cheap Chinese imports in the country after the steep US tariff hike on the goods exported by the Communist country.
Rupee strengthens against dollar amid Trump's reciprocal tariffs
The Indian rupee witnessed sharp gains on Friday at below 85 against dollar, as the dollar index and oil prices dropped sharply amid concerns over recession in the US economy after the reciprocal tariffs were announced.
Sensex, Nifty open lower amid weak global cues post Trump tariffs
Indian frontline indices opened in the red on Friday following global sell-off in the equity markets in reaction to the reciprocal tariffs announced by US President Donald Trump.
Sensex, Nifty open lower as Trump tariffs trigger global sell-off
Indian equity indices opened lower on Thursday following a sharp sell-off in global markets after the US President Donald Trump announcement of reciprocal tariffs.
India stands less impacted by Trump tariffs than global peers: Industry
As US President Donald Trump announced reciprocal tariffs on dozens of countries, including India, industry experts said on Thursday that it appears India's export competitiveness to the US market stands far less impacted on a relative basis compared to global peers.
Sensex, Nifty end higher ahead of US reciprocal tariffs announcement
The Indian stock market bounced back on Wednesday, with both the Sensex and Nifty closing higher, just before the reciprocal tariffs deadline set by US President Donald Trump.
Early April critical for investors’ sentiment amid key economic data: Report
Early April will be critical for market sentiment, with key economic data releases providing insights into global manufacturing, employment trends and economic activity, a report showed on Monday.
Foreign investors pump Rs 31,000 crore into Indian stocks as market rebounds
Foreign investors have injected nearly Rs 31,000 crore into Indian equity markets in the last six trading sessions of March, according to the latest depository data.